Wolverine Stack (BPC-157 + TB-500)
A research overview of the combination of BPC-157 and TB-500, two peptides studied for tissue repair, angiogenesis, and recovery from musculoskeletal injury. BPC-157 is a gastric peptide with Human Trials evidence across multiple tissue types. TB-500 is a synthetic thymosin beta-4 fragment with Animal Studies evidence for regenerative and anti-inflammatory activity.
Science simplified
The Wolverine Stack combines BPC-157 and TB-500 (two of the most researched tissue repair peptides) into a single recovery protocol. BPC-157 targets localized injury repair at the cellular level while TB-500 works systemically to reduce inflammation and help cells migrate to damaged tissue. Together they address recovery from two complementary directions. All evidence is from animal studies, no human clinical trials exist for this combination.
Best researched for
Tendon · ligament · muscle injury recovery
Evidence stage
Strong animal data · no human combination trials
Approval status
Neither compound FDA-approved · research use only
Human Trials / Animal Studies
Compound Evidence Levels
None
Combination Trial Data
2
Compounds
Tissue Repair
Primary Research Focus
PSI Verdict
Supported by evidence
BPC-157 and TB-500 address tissue repair through genuinely distinct mechanisms. BPC-157 drives localized angiogenesis and growth factor signaling. TB-500 promotes systemic cell migration and anti-inflammatory activity via actin upregulation. The mechanistic complementarity is real and well-characterized at the individual compound level. Both compounds have consistent preclinical evidence for tissue repair independently.
Not yet established
No controlled studies have evaluated BPC-157 and TB-500 in combination. The synergy hypothesis is mechanistic reasoning, not observed data. Whether the compounds interact pharmacokinetically, produce additive or synergistic outcomes, or carry additional safety considerations when combined is entirely unknown.
Confidence level
The Wolverine Stack has the most credible mechanistic rationale of any stack in this library. Two compounds with distinct, complementary repair mechanisms and strong independent preclinical profiles. The combination itself has never been studied. That gap matters and should not be rationalized away by the quality of the individual compound evidence.
Stack Rationale
BPC-157: Promotes angiogenesis, growth factor signaling, and tendon/ligament repair via VEGF and GH receptor pathways. BPC-157 is a gastric pentadecapeptide with strong preclinical data across multiple tissue types including tendon, ligament, muscle, bone, and gut mucosa.
TB-500: Promotes cell migration via actin upregulation and reduces inflammation via TNF-α and IL-6 suppression. TB-500 is a synthetic fragment of thymosin beta-4 studied for regenerative effects across musculoskeletal, cardiac, and dermal tissue.
Theoretical rationale: The mechanistic complementarity hypothesis proposes that BPC-157 drives vascular and structural repair while TB-500 drives cellular migration and anti-inflammatory activity. These are mechanistically distinct compounds with no overlap in primary mechanism. This rationale is mechanistic and has not been tested in combination trials.
Important limitation: No clinical or preclinical studies have evaluated BPC-157 and TB-500 in combination. The stack rationale is derived entirely from the individual compound profiles. Interaction effects, safety of combined use, and additive or synergistic outcomes are unknown.
In everyday terms: BPC-157 acts like a targeted repair signal at the injury site, promoting new blood vessel growth and tissue rebuilding. TB-500 works more broadly across the whole body, helping cells move to where they are needed and reducing the inflammation that slows healing. Together they address recovery from two different but complementary directions.
Compound Profiles
A gastric pentadecapeptide that promotes angiogenesis and growth factor signaling across multiple tissue types. Strong and consistent animal data for tendon, ligament, muscle, bone, and gut repair. Limited human clinical data. Classified as Human Trials (Moderate Evidence) based on the breadth and consistency of preclinical findings.
A synthetic fragment of thymosin beta-4 that promotes actin-mediated cell migration and anti-inflammatory signaling. Early-phase human trial data exists for wound healing via the parent molecule thymosin beta-4. Musculoskeletal applications remain primarily preclinical. Classified as Animal Studies (Preliminary Evidence).
Mechanistic Comparison
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric peptide fragment | Thymosin beta-4 synthetic fragment |
| Primary mechanism | Angiogenesis + GH receptor signaling | Actin upregulation + cell migration |
| Anti-inflammatory | Moderate via growth factors | Strong via TNF-α and IL-6 suppression |
| Tissue targets | Tendon, ligament, gut, bone | Musculoskeletal, cardiac, dermal |
| Evidence level | Human Trials | Animal Studies |
| Human data | Limited human | Very limited human |
Evidence Summary
What people commonly research this for
- , Tendon, ligament, and muscle injury recovery
- , Post-surgical tissue repair support
- , Athletic recovery and injury prevention research
All evidence is from animal studies. No human combination trials exist. Not FDA-approved.
Individual Compound Evidence
BPC-157 is rated Human Trials (Moderate Evidence) with strong and consistent animal data across multiple tissue types and limited human clinical data. No human clinical data exists for cardiovascular health. TB-500 is rated Animal Studies (Preliminary Evidence) with early-phase human trial data for wound healing via thymosin beta-4, while musculoskeletal applications remain primarily preclinical.
Combination Evidence
No controlled studies have evaluated BPC-157 and TB-500 in combination. The stack rationale is mechanistic. Whether the compounds interact pharmacokinetically, produce additive or synergistic repair effects, or carry additional safety considerations when combined is not established in published research.
Safety Considerations
Individual Safety Profiles
BPC-157 has a favorable safety profile in animal studies with limited human safety data available. TB-500, via the parent molecule thymosin beta-4, has early-phase human trial data showing a generally favorable safety profile in wound healing contexts.
Combination Safety. Unknown
No safety data exists for combined use of BPC-157 and TB-500. Drug interaction potential, combined tissue effects, and cumulative dosing considerations have not been studied. The apparent mechanistic complementarity does not guarantee safety in combination. Caution is warranted.
Research Context
Researchers interested in the individual mechanisms behind this stack can review the full compound profiles for BPC-157 and TB-500.
A direct mechanistic comparison of the two compounds is available in the BPC-157 vs TB-500 comparison.
For a broader overview of peptides studied for musculoskeletal growth and repair, see the peptides for muscle growth roundup.
This stack is reviewed in the context of the broader injury recovery research literature on this site.
Medical Disclaimer
This page is for informational and educational purposes only and does not constitute medical advice. BPC-157 and TB-500 are research compounds not approved for human therapeutic use. Always consult a qualified healthcare professional. PSI aggregates publicly available research and does not conduct original clinical trials.